Recursion, a Salt Lake City company, has reached an agreement with the FDA on the design of a registrational Phase 3 trial of REC-4881, an investigational oral MEK1/2 inhibitor for adults with familial adenomatous polyposis (FAP). The trial’s primary endpoint, event-free survival, will count removal of an adenoma 10 mm or larger in either the upper or lower GI tract as an event.
The company aims to launch the study between July and December 2027, targeting roughly 200 participants in a randomized, double-blind test comparing REC-4881 to a placebo. The trial will assess a 4 mg dosage, with the treatment schedule determined by findings from the ongoing TUPELO study.
Trial Design and Endpoints
The trial’s primary endpoint will measure time from randomization to the first qualifying event, which includes removal of an adenoma 10 mm or larger, meeting prespecified criteria for FAP-related surgery, developing high-grade dysplasia or cancer, and death. Evelien Dekker, a professor of gastrointestinal oncology at Amsterdam University Medical Center, noted that adenomas 10 millimeters and larger are associated with increased cancer risk and are routinely removed in patients with FAP.
Among the key secondary measures are changes in duodenal polyp severity using the modified Spigelman scale and overall polyp counts. This approach follows up on the Phase 1b/2 TUPELO trial, which previously showed a 47% median reduction in total polyps after 12 weeks of daily 4 mg REC-4881 in 15 patients.
Background and Context
FAP is caused by mutations in the APC gene and currently has no FDA-approved drug therapy. Without surgery to remove the colon, the lifetime risk of colorectal cancer in people with classic FAP approaches 100%. Patients face lifelong endoscopic surveillance, repeated polyp removal, and, in some cases, further major surgery.
Recursion licensed REC-4881 from Takeda in 2020 and used phenotypic screening with its AI models to identify the drug’s potential in FAP. They reopened enrollment to adults 18 and older in the TUPELO trial after initially narrowing it to patients 55 and older to evaluate adverse events.
Another company, Biodexa Pharmaceuticals, is already running a registrational Phase 3 trial of eRapa, an oral formulation of rapamycin, in patients with FAP, and has enrolled 112 of a planned 168 participants. Recursion’s trial will provide further insight into the potential of REC-4881 in treating FAP, and it is expected to start soon.
